Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

Expanded access is currently available for this treatment.
Verified July 2016 by Stanford University
Information provided by (Responsible Party):
Andrei Iagaru, Stanford University Identifier:
First received: November 4, 2013
Last updated: September 13, 2016
Last verified: July 2016
The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

Condition Intervention Phase
Carcinoid Tumors
Islet Cell (Pancreatic NET)
Other Neuroendocrine Tumors
Drug: 68Ga-DOTA TATE
Phase 2

Study Type: Expanded Access     What is Expanded Access?
Official Title: 68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors

Resource links provided by NLM:

Further study details as provided by Stanford University:

Study Start Date: November 2013
Estimated Study Completion Date: November 2019
Estimated Primary Completion Date: November 2018 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: 68Ga-DOTA TATE
    Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTA TATE PET/CT in addition to conventional imaging.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Greater than 18 years-old at the time of radiotracer administration
  • Provides written informed consent
  • Known diagnosis of NET or suspected SSTR positive tumors by 111In-Octreotide scan, 18FDG-PET, or MRI of the abdomen when clinically indicated
  • Karnofsky score greater than 50 or ECOG Performance Status 0-2
  • Women of childbearing age must have a negative pregnancy test at screening/baseline
  • Able to remain still for duration of each imaging procedure (about one hour)

Exclusion Criteria:

  • Less than 18 years-old at the time of radiotracer administration
  • Pregnant or nursing
  • Serum creatinine >3.0 mg/dL
  • Hepatic enzyme levels more than 5 times upper limit of normal.
  • Use of any other investigational product or device within 30 days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments.
  • Inability to lie still for the entire imaging time
  • Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
  • Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01980732

Contact: Amanda Remillard 650-721-4091

United States, California
Stanford University Cancer Institute
Stanford, California, United States, 94305
Contact: Krithika Rupnarayan    650-736-0959   
Principal Investigator: Andrei Iagaru         
Sponsors and Collaborators
Andrei Iagaru
Principal Investigator: Andrei Iagaru Stanford University
  More Information

Responsible Party: Andrei Iagaru, Assistant Professor of Radiology - Nuclear Medicine, Stanford University Identifier: NCT01980732     History of Changes
Other Study ID Numbers: NET0017
Study First Received: November 4, 2013
Last Updated: September 13, 2016

Additional relevant MeSH terms:
Neuroendocrine Tumors
Carcinoid Tumor
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms, Glandular and Epithelial
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on April 27, 2017